View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 8, 2020

Indian Immunologicals, Griffith University to develop Covid-19 vaccine

Vaccine manufacturer Indian Immunologicals and Griffith University in Australia have partnered to develop a potential vaccine candidate against Covid-19.

Vaccine manufacturer Indian Immunologicals and Griffith University in Australia have partnered to develop a potential vaccine candidate against Covid-19.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

The partners intend to create a live attenuated vaccine using codon de-optimisation technology, which would offer longer protection with a single dose.

In a statement, Indian Immunologicals said: “The technology looks promising for developing a vaccine for prophylactic, active, single-dose immunisation against coronavirus in humans, with an enhanced safety profile.

“The vaccine is expected to provide long-lasting protection with a single dose administration with an anticipated safety profile similar to other licensed vaccines for active immunisation.”

After research completion, the vaccine strain will be transferred to the company, which will be responsible for further development, including clinical trials.

The company plans to use its Vero cell platform technology for mass production of the vaccine.

Griffith University Menzies Health Institute Queensland researcher Suresh Mahalingam said: “As this vaccine will be a live attenuated vaccine it is expected to be highly effective by providing very strong cellular and antibody immune responses against the virus.

“The other benefit of a live-attenuated vaccine is a proven track record for economical large-scale manufacturing and well-known regulatory approval pathway.”

Previously, Indian Immunologicals partnered with the Australian university for the research and development of Zika virus vaccine, now undergoing pre-clinical toxicology testing.

In February, Serum Institute of India forged an alliance with US-based Codagenix to develop a Covid-19 vaccine candidate. The vaccine candidate entered animal testing phase and data from mice and primates is expected by the end of August.

Serum Institute of India estimates that the vaccine candidate will enter clinical trials in the coming six months.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU